Journal Watch · Clinical Cancer Research · 2026

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy.

Nonnekens J, Byers LA, Chauhan A et al.Clinical Cancer Research3 min readPharma relevance 85/100

DOI: 10.1158/1078-0432.ccr-25-4720PMID: 42439911Study type: review / perspective

TL;DR

Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy.

Key findings

  • We discuss the preclinical rationale, available clinical data, and ongoing key clinical trials with TRT combination therapy.
  • Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy.

What they did

However, most patients eventually relapse following TRT monotherapy, leaving room to further improve patient outcomes. Combination strategies could be beneficial to improve therapeutic index, enhance cytotoxic effects, or modulate tumor target expression; promising preclinical data have led to early-phase clinical trials. This review provides a concise overview of physical and chemical properties of commonly used β- and α-emitting radionuclides and a forward-looking rationale for combination regimens of TRT and other therapeutic modalities, such as hormone therapy, DNA damage repair inhibitors, immunotherapy, chemotherapy, external beam radiotherapy, and other combinations.

Full abstract (original)

Background: Targeted radionuclide therapy (TRT) is an emerging modality in oncology that delivers internal radiation specifically to tumor sites. It typically consists of a particle-emitting radionuclide, a linking complex with a chelator for securely binding radionuclides to targeting molecules, and a binding moiety of targets expressed on tumor cells. Early clinical results have been promising, with several TRT agents approved for treating various cancers, including prostate cancer and gastroenteropancreatic neuroendocrine tumors, or their microenvironment.

What they did: However, most patients eventually relapse following TRT monotherapy, leaving room to further improve patient outcomes. Combination strategies could be beneficial to improve therapeutic index, enhance cytotoxic effects, or modulate tumor target expression; promising preclinical data have led to early-phase clinical trials. This review provides a concise overview of physical and chemical properties of commonly used β- and α-emitting radionuclides and a forward-looking rationale for combination regimens of TRT and other therapeutic modalities, such as hormone therapy, DNA damage repair inhibitors, immunotherapy, chemotherapy, external beam radiotherapy, and other combinations.

Results & conclusions: We discuss the preclinical rationale, available clinical data, and ongoing key clinical trials with TRT combination therapy. Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy.

Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-25-4720 · PubMed 42439911.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Cancer Research study find?

Additionally, we highlight future perspectives including emerging radionuclides and prognostic and predictive biomarkers to optimize TRT combination therapy.

What type of study is this?

It is a review / perspective, published in Clinical Cancer Research in 2026. However, most patients eventually relapse following TRT monotherapy, leaving room to further improve patient outcomes.

Where can I read the original paper?

The original is at the publisher via DOI 10.1158/1078-0432.ccr-25-4720. PubMed ID: 42439911. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Nonnekens J, Byers LA, Chauhan A et al.. Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.. Clinical Cancer Research (2026). DOI: 10.1158/1078-0432.ccr-25-4720.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeted-radionuclide-therapy-current-landscape-and-combination-approach-254720/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides